A Phase II Pilot Study of yttriuM-90 in Combination With capEcitabine and aTezolizumab for oligomEtastatic cOlorectal Cancer With unResectable lIver MeTastasEs (METEORITE)

BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.

开始日期2024-08-30

申办/合作机构

Brown University

[+2]

NCT05692037 / Recruiting临床1/2期IIT

Yttrium-90 Carbon Microspheres in Patients With Unresectable Colorectal Liver Metastases: A Multicentre, Prospective, Open-label, Single-arm Trial

To evaluate the efficacy and safety of yttrium-90 carbon microspheres in patients with unresectable colorectal liver metastases

开始日期2022-12-28

申办/合作机构

东南大学附属中大医院

NCT05620771 / Recruiting临床2期IIT

Phase II Study Therasphere® (Yttrium-90) in Combination With Systemic Therapy in Patients With High-risk Hepatocellular Carcinoma

The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy consists of a standard-of-care treatment with Atezolizumab and Bevacizumab. Treatment with tyrosine kinase inhibitors consists of standard-of-care Lenvatinib or Cabozantinib.

开始日期2022-11-30

申办/合作机构

Northwestern University

[+1]

100 项与钇90 相关的临床结果

登录后查看更多信息

100 项与钇90 相关的转化医学

登录后查看更多信息

100 项与钇90 相关的专利（医药）

登录后查看更多信息

1,092

项与钇90 相关的文献（医药）

2024-12-01·American journal of ophthalmology case reports

Yttrium-90 (90Y) brachytherapy for squamous carcinoma: Treatment of the conjunctiva, cornea, and sclera

Article

作者: Finger, Paul T ; Maniar, Arpita ; Materin, Miguel A. ; Chino, Junzo ; Meltsner, Sheridan ; Materin, Miguel A ; Finger, Paul T.

Purpose:

Patients with conjunctival squamous cell carcinoma that present with persisting disease or recurrence following topical chemotherapy and/or surgery especially when invading the sclera are challenging to treat. Herein, we describe the use of high-dose-rate (HDR), FDA-cleared, yttrium-90 (⁹⁰Y) plaque brachytherapy for such lesions.

Observation:

Three cases of invasive conjunctival squamous cell carcinoma that had exhibited a poor response or recurrence following topical chemotherapy and/or surgery are described. As treatment, HDR ⁹⁰Y beta-radiation was applied to the tumor and margins for a single, continuous duration. In contrast to low-dose-rate (LDR) plaque, HDR ⁹⁰Y brachytherapy did not require episcleral sutures, amniotic membrane buffering of the cornea, a Gunderson flap, outpatient dwell time, or second surgery. Radiation safety was improved by eliminating LDR-implant related post-operative radiation exposure to health care personnel, the community, family, and pets. Follow-up examination at one month revealed complete tumor resolution in all patients. At last follow-up (8, 11 and 18 months) all patients remained clinically tumor-free as confirmed by slit-lamp biomicroscopy, anterior segment optical coherence tomography, and high-frequency ultrasound imaging. There were no acute complications (e.g., corneal edema, iridocyclitis, scleropathy, keratopathy or cataract).

Conclusion and Importance:

⁹⁰Y brachytherapy demonstrated efficacy as a single-surgery, minimally invasive, outpatient irradiation for squamous carcinoma of the ocular surface. While short-term results were promising, long-term follow-up monitoring for side-effects and recurrence are essential.

2024-11-01·JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY

Outcomes Analysis of Yttrium-90 Radioembolization for Tumors Other Than Metastatic Colorectal Cancer from the Radiation-Emitting SIR-Spheres in Nonresectable (RESiN) Registry

Article

作者: Du, Liping ; Brown, Daniel B ; Zhou, Wenhui ; Sze, Daniel Y ; Shah, Rajesh P

PURPOSE:

To characterize the response and survival outcomes of yttrium-90 (⁹⁰Y) transarterial radioembolization (TARE) for unresectable, liver-dominant metastases from primary neoplasms other than colorectal carcinoma.

MATERIALS AND METHODS:

This study included 1,474 patients enrolled in the Radiation-Emitting Society of Interventional Radiology (SIR)-Spheres in Nonresectable Liver Tumor registry who received resin ⁹⁰Y-TARE as part of their oncologic management for unresectable primary or secondary liver tumors (NCT02685631). Of these patients, 33% (481/1,474) were treated for liver metastases of noncolorectal origin (m-non-CRC) compared with 34% (497/1,474) treated for metastatic colorectal cancer (mCRC) and 34% (496/1,474) treated for hepatocellular carcinoma. Treatment response and cancer survival probabilities were computed and compared for each primary cancer type. The Kaplan-Meier method and log-rank test were used to compare survival outcomes.

RESULTS:

Radiological responses were observed in 12 unique cancer types, mostly heavily pretreated malignancies refractory to multiple lines of systemic therapies. The overall use of resin ⁹⁰Y-TARE in m-non-CRC resulted in better treatment outcomes in terms of duration of response, progression-free survival, time to progression, and overall survival (P = .04, P = .02, P = .01, and P = .04, respectively). Analyses of cancer cell types revealed that metastatic neuroendocrine tumor, sarcoma, and ovarian, renal, prostate, and breast cancers were associated with superior treatment outcomes, whereas worse treatment outcomes were observed in metastatic lung, gastric, pancreatic, and esophageal cancers.

CONCLUSIONS:

Real-world data demonstrate the use of resin ⁹⁰Y-TARE in m-non-CRC refractory to standard chemotherapy. For some cell types, this expanded use achieved superior treatment outcomes relative to the reference standard of mCRC, suggesting the need for inquiry into broadened indications for ⁹⁰Y-TARE.

2024-10-01·JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY

Resin-based Yttrium-90 Radioembolization as a Bridging or Downstaging Treatment to Liver Transplantation for Hepatocellular Carcinoma

Article

作者: Van Laeken, Charlotte ; Pirenne, Jacques ; Bonne, Lawrence ; Dekervel, Jeroen ; Verslype, Chris ; Deroose, Christophe M ; Deroose, Christophe M. ; Vandecaveye, Vincent ; Maleux, Geert ; Monbaliu, Diethard ; Laenen, Annouschka

PURPOSE:

To evaluate the outcomes of resin-based yttrium-90 radioembolization (TARE) for hepatocellular carcinoma (HCC) as a bridging or downstaging therapy to liver transplantation (LT) in terms of safety, tumor response, recurrence, and survival.

MATERIALS & METHODS:

A single-center retrospective analysis of patients with HCC treated with resin-based TARE as bridging or downstaging treatment to LT between January 2006 and April 2021 was performed. TARE-related liver toxicity was assessed. Imaging data were analyzed to assess tumor response. Histopathological analysis of explant livers was performed to assess HCC necrosis. Survival and bridging/downstaging success predictor analysis was performed.

RESULTS:

Thirty-six patients underwent resin-based TARE with the intention to bridge (33%) or downstage (67%) to LT. 44% had ≥3 HCC lesions, 53% had bilobar disease. Median largest tumor diameter was 3.4 cm. TARE was segmental, lobar, and bilobar in 20%, 36%, and 44% of cases, respectively. 17% had grade 3 bilirubin toxicities. Objective response rate per mRECIST was 72%. Patients meeting UNOS-DS criteria had higher chances of successful bridging/downstaging. 23 patients were transplanted. Complete pathologic response was seen in 30% of explant livers. Post-transplant tumor recurrence occurred in 26% within a median follow-up period of 1710 days. Estimated 5-year progression-free, disease-specific, and overall survival rates after LT were 89%, 69%, and 89%, respectively. For the entire patient cohort, these rates were 87%, 53% and 70%.

CONCLUSION:

Resin-based ⁹⁰Y TARE can be considered a valuable treatment option for bridging or downstaging patients with HCC to LT, including patients requiring (bi-)lobar TARE for extensive tumoral disease.

项与钇90 相关的新闻（医药）

2024-09-16

·PRNewswire

Sirtex Medical Announces Certification of SIR-Spheres® Y-90 Resin Microspheres According to Medical Device Regulation (EU) 2017/745 and European Launch of the Innovative SIROS™ Delivery System

Sirtex brings an innovative liver cancer treatment delivery system to Europe, enhancing options for physicians and their patients. WOBURN, Mass., Sept. 16, 2024 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, today announced that it has received certification according to Medical Device Regulation (EU) 2017/745 for SIR-Spheres® Y-90 resin microspheres and its delivery systems, paving the way for the European launch of the SIROS™ Delivery System. The EU MDR places greater emphasis on patient safety measures, risk management, post-market surveillance, and comprehensive data collection for medical devices seeking European market access. "Patient health and safety are always at the forefront of our work. That is why we are particularly proud to receive EU MDR certification for SIR-Spheres® Y-90 resin microspheres and its delivery systems, including SIROS™. This achievement underscores our commitment to delivering innovative products responsibly and ethically," said Matt Schmidt, CEO of Sirtex Medical Inc. "With the expansion of SIROS™ outside of the U.S., interventional radiologists in Europe now have an additional option to support patients battling metastatic colorectal cancer (mCRC) and unresectable hepatocellular carcinoma (HCC). This milestone reflects the outstanding efforts of our team, the rapid growth of our business, and the groundbreaking interventional oncology solutions we have developed." The SIROS™ Delivery System offers an intuitive, visual, and adaptable solution for physicians to administer SIR-Spheres® to liver cancer patients. Its easy-to-use design along with controlled administration provides physicians confidence in the Y-90 delivery. "As an interventional radiologist, I am excited about the future use of the SIROS™ Delivery System," shared Professor Thomas Helmberger, Head of Department of Radiology, Neuroradiology, and Minimal-Invasive Therapy at München Klinik Bogenhausen in Munich, Germany. "This device has an intuitive design and a precise control that will facilitate the administration of SIR-Spheres® Y-90 resin microspheres, and I am looking forward to incorporating it into my practice." About SIR-Spheres® in Europe SIR-Spheres® are medical devices used in selective internal radiation therapy (SIRT) and are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer (mCRC) in patients refractory to or intolerant of chemotherapy. For a complete listing of indications, contraindications, side effects, warnings, and precautions, please consult the Instructions for Use at . About Sirtex Sirtex is a global healthcare company with offices in the U.S., Australia, Europe, and Asia, dedicated to improving patients' quality of life and longevity through innovative, minimally invasive cancer and embolization therapies. Sirtex's current leading product, SIR-Spheres® Y-90 resin microspheres, offers targeted radiation therapy for liver cancer. For more information, visit . SOURCE Sirtex Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

放射疗法

2024-08-16

·动脉网

自研强流电子直线加速器，德睿光核加速医用同位素国产替代

当下，核药无疑是创新药领域的“当红炸子鸡”，备受产业界及资本市场的关注与青睐。尤其是2024年以来，核药投融资与交易市场更是呈现出火热态势。据动脉网不完全统计，2024年截至目前，全球共有12家核药领域企业获得融资，融资总额超过68亿元。此外，全球范围内的核药合作与交易不断，2024年以来已有9笔重磅交易诞生，交易潜在总金额超过100亿美元。不过，核药的发展并非一路坦途。在核药投融资与交易市场发展如火如荼的另一面，仍面临着医用同位素全球短缺、药物配送产业链不完备等问题。其中，医用同位素产能短缺一直被视为核药产业化的头号限制因素。加速医用同位素量产，成为跨越核药商业化应用门槛的关键因素之一。德睿光核（深圳）科技有限公司（以下简称“德睿光核”）是一家致力于通过自主研发强流电子加速器，制备医用同位素，以为核药企业、医院以及科研院所提供核药原料的创新企业。发展至今，德睿光核突破了“高能电子加速器”关键技术难点，并完成了40MeV/40kW强流电子直线加速器相关技术验证以及对核心技术申请了相关专利保护。目前，公司正在推进首台40MeV/40kW强流电子直线加速器的建造过程。世界级加速器专家领衔，具备20年研发与工程经验医用同位素是核药最重要的原料之一，目前主要通过反应堆、加速器以及同位素发生器三种方式生产。其中，反应堆辐照是获得医用同位素最重要的方式，80%以上的医用同位素由其产生，包括常用的医用同位素99Mo/99mTc、I-131、Sr-89、Lu-177、Y-90、C -14等。值得一提的是，目前医用同位素反应堆集中度高，大量反应堆集中在欧美地区。这些地区的反应堆供应量超过全球供应量的90%。此外，我国目前主要有5座反应堆可用于医用同位素的生产和制备。但由于多种原因限制，我国自主生产的碘-131、锶-89仅满足国内20%的需求，镥-177仅满足国内5%的需求，其他常用堆照医用同位素都依赖于进口，产业链稳定性不高。 99Mo供应链参与者及分销渠道图源：德睿光核与此同时，目前国际上生产医用同位素的反应堆运行时间大多超过40年，预计到2030年，多个现役反应堆将关停。届时，全球医用同位素供应将出现巨大的产能缺口，全球性核素短缺进程将加速到来。在此情况下，加速器因其成本低、损耗少、供给稳定等优势，成为突破医用同位素短缺困境的关键技术。德睿光核COO&联合创始人李宇徒表示：“与反应堆相比，加速器在实现商业化方面具有一定的便捷性。但是，我国目前用于医用同位素生产的加速器大部分仍依靠进口。”于是，为了扭转这一局面，李宇徒联合黄永盛教授及其团队，在2024年6月共同创立了德睿光核。目前，德睿光核搭建了一个具有20年研发与工程经验、加速技术全球领先的核心团队。团队成员来自清华大学、中山大学、中科院高能所、中科院应物所、武汉大学和西北工业大学等，曾主导或参与国内80%以上的高能直线加速器项目。重要的是，公司核心团队由黄永盛教授领衔。黄永盛教授毕业于清华大学工程物理系，现任中山大学理学院副院长。他是一位知名的粒子物理和核物理以及等离子体物理专家，世界首台伽玛光子对撞机设计者。 “强流+高能+电子+直线”加速器方案，可高效生产多种医用同位素在黄永盛教授的带领及团队的推动下，德睿光核突破了电子加速器制备医用同位素的技术难点，正在加速推进首台40MeV/40kW强流电子直线加速器的建造过程。其中，德睿光核自主研发的强流电子加速器的技术原理是：通过强流高能电子加速器产生高能电子，用高能电子轰击转换靶产生γ射线，用γ射线轰击同位素靶材，诱发光核反应，从而产生医用同位素。图源：德睿光核而通过加速器制备医用同位素，需要克服三大技术难点——靶材原料、分离纯化、加速器。以制备医用同位素钼-99（99Mo）为例。在靶材原料方面，在核医学领域，高丰度钼-98和钼-100同位素是生产放射性同位素钼-99的前置核素。因此，通过加速器制备钼-99，需要大量的靶材原料钼-100。而后，通过加速器产生高能电子，用高能电子轰击转换靶产生γ射线，用γ射线轰击钼-100，诱发钼-100(γ, n) 光核反应，从而产生钼-99。此前，国内钼同位素材料长期依赖进口。不过，在2023年，中核集团核理化院通过自主研发首次获得公斤级丰度99%钼-100同位素，改变了我国长期以来钼同位素完全依赖进口的局面。“这也意味着，钼-100的后续供应对于德睿光核而言将不成问题。”李宇徒说道。在分离纯化方面，由于传统制备钼-99的方式是采用浓缩铀，即通过铀-235的裂变来启动反应。但在裂变反应中，会生成一系列具有不同性质的核素混合物，其化学性质和物理性质存在差异，使得分离和纯化钼-99的过程极具挑战性。对此，德睿光核的加速器通过采用稳定同位素钼-100、经过光核反应制备钼-99。在这过程中，其产生其他放射性核素的概率低于传统核反应方式。这是因为，在使用特定能量的γ射线轰击特定的靶核时，可能会伴随产生一些半衰期较短、放射性较弱的核素。但它们的量相对较少，且经过一定时间的衰变后，其放射性影响会显著降低。最终，钼-99的分离纯化也将变得相对简单。图源：德睿光核最后，在加速器核心技术方面。需要注意的是，核素的制备对于加速器有着诸多高要求。首先，在能量方面，加速器需要达到特定的高能水平，以引发所需的核反应。其次，加速器的流强要求也很高。强大且稳定的流强能够提高反应的效率和产率，从而在单位时间内生产出更多种类不同的目标核素。对此，李宇徒也表示：“制备核素的加速器，既要‘高能’又要‘强流’，电子束能量要达到40MeV，平均流强要达到1mA。并且建造成本也应控制得住。否则，便难以实现加速器的商业化生产。” 针对这一点，德睿光核已突破“高能电子加速器”关键技术，并完成了 40MeV/40kW强流电子直线加速器相关技术验证，目前正在推进首台高能电子加速器的设计建造过程。正在启动新一轮融资，加速建造首台强流电子直线加速器尽管成立时间仅有2个多月，但德睿光核正在加快迈向实现“研发加速器替代反应堆、建立医用同位素生产新范式”发展目标的步伐。目前，德睿光核正在加速制造首台用于制备医用同位素的强流电子直线加速器。建成后，其将成为全国首台商用的高能强流电子加速器，公司也有望成为全国首家实现“商业化量产”的器产同位素生产商。同时，德睿光核正在推动首条钼-99制备产线的建设与投产运行。在这过程中，德睿光核积极寻求与钼锝核药以及放射性核素偶联药物（RDC）领域的创新药企的合作，以共同推动核素生产线的建造过程。《医用同位素中长期发展规划（2021—2035年）》指出，到2025年，一批医用同位素发展的关键核心技术要取得突破，并根据市场需求，适时启动建设1—2座医用同位素专用生产堆，实现常用医用同位素的稳定自主供应；到2035年，在充分保障我国人民健康需求的基础上，积极推动医用同位素“走出去”，为构建人类卫生健康共同体做出贡献。李宇徒表示：“德睿光核首台加速器建成投产后，不仅能够加速扭转国内医用同位素长期依赖进口供应的局面，还将大幅降低其生产成本。此外，由于该制备系统采用‘无铀（浓缩铀）无堆（反应堆）’技术路线，因而其具有总体造价低、分离工艺简单、无核废料、对环境友好等优势，是一种能够替代反应堆的颠覆式放射性医用同位素生产技术。” 未来，在钼-99制备产线的基础上，德睿光核将进一步扩大医用同位素的制备范围，与全球企业合作，以强流电子直线加速器为基础，共同建造其他核素生产线，从而实现67Cu、47Sc、225Ac、212Pb等其他种类医用同位素的制备。在实现常用医用同位素国产替代的基础上，德睿光核将积极拓展产品线与海外市场，最终促进核药产业的稳步发展。目前，德睿光核正在开启新一轮融资。与此同时，德睿光核正在积极扩建团队，期待核药和核素行业内的精英人士加入其中。如果您想对接文章中提到的项目，或您的项目想被动脉网报道，或者发布融资新闻，请与我们联系；也可加入动脉网行业社群，结交更多志同道合的好友。近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。动脉网，未来医疗服务平台

2024-08-05

·PRNewswire

Sirtex Medical Launches SIR-Spheres® FLEXdose SELECT Delivery Program to Enable More Selective Y-90 Treatment Plans

Sirtex announces SIR-Spheres® portfolio expansion to include the FLEXdose SELECT 3mL vial configuration allowing for more patient-specific Y-90 selective treatment plans WOBURN, Mass., Aug. 5, 2024 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, announced today the launch of its SIR-Spheres® FLEXdose SELECT Delivery Program, an innovative, new way to offer precise Y-90 selective internal radiation therapy for the treatment of metastatic colorectal cancer. SIR-Spheres® FLEXdose SELECT Delivery Program offers unparalleled flexibility by enabling tailored, patient-specific dosing from a single 3mL delivery vial. This program also marks the availability of 3mL SIR-Spheres® vials, which contain a reduced volume of microspheres (approximately 27 million compared to 44 million in the current 5mL vials). With up to five days pre-calibration available every day of the week, the novel Y-90 delivery program offers a vial of SIR-Spheres® designed for more selective treatment targeting. "We're pleased to introduce this latest innovation in Y-90 radioembolization therapy to treat a broader spectrum of tumor burden," said Matt Schmidt, CEO of Sirtex Medical Limited. "The SIR-Spheres® FLEXdose SELECT Delivery Program reflects our continued focus on listening to the needs of patients and physicians by enabling access to personalized Y-90 resin doses and expedited patient treatments." "I have found the SIR-Spheres® FLEXdose Program to be extremely helpful in treating my patients on a timely basis," explained Ripal Gandhi, M.D., a member of the Miami Cardiac & Vascular Institute and Miami Cancer Institute and the course director for the Symposium on Clinical Interventional Oncology. "With this program, I can personalize the Y-90 treatment for each of my patients using a product that is available every day of the week. I applaud Sirtex for investing resources in SIR-Spheres® FLEXdose SELECT and providing more options for physicians to optimize treatment strategies for even more patients." The new 3mL SIR-Spheres® Y-90 resin microspheres vials are available for order at [email protected]. For more information and details on how to incorporate the SIR-Spheres® FLEXdose SELECT Delivery Program into your practice, please contact Sirtex at [email protected]. About SIR-Spheres SIR-Spheres® are a medical device used in selective internal radiation therapy). SIR-Spheres® are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Caution: Federal (USA) law restricts this device for sale by or on the order of a physician. Consult the Instructions for Use () for a complete listing of indications, contraindications, side effects, warnings and precautions. About Sirtex Sirtex is a global healthcare business with offices in the U.S., Australia, Europe and Asia, working to improve outcomes in people with cancer. Sirtex's current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. For more information, visit . SOURCE Sirtex Medical Inc.

放射疗法

100 项与钇90 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	V09	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
诊断试剂	欧盟	CIS Bio International SA	2003-03-24
诊断试剂	冰岛	CIS Bio International SA	2003-03-24
诊断试剂	列支敦士登	CIS Bio International SA	2003-03-24
诊断试剂	挪威	CIS Bio International SA	2003-03-24

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝细胞癌	临床3期	中国	昆翎（天津）医药发展有限公司	2021-09-13
肝细胞癌	临床3期	中国	Biocompatibles UK Ltd.	2021-09-13
神经内分泌肿瘤	临床2期	波兰	Uniwersytet Warminsko Mazurski	2004-11-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EASL_LCS2024	N/A	肝细胞癌	150	resin 90Y	餘壓膚蓋憲顧蓋鹽網鹹(鹽築網憲願簾獵壓餘顧) = 繭窪鬱鑰壓簾獵淵齋膚鬱繭築製艱積願鏇齋淵 (積願窪鑰壓製範鬱窪鏇 ) 更多	积极	2024-02-22
				resin 90Y	餘壓膚蓋憲顧蓋鹽網鹹(鹽築網憲願簾獵壓餘顧) = 簾網繭餘觸願繭製築範鬱繭築製艱積願鏇齋淵 (積願窪鑰壓製範鬱窪鏇 ) 更多
SNMMI2022	N/A	肝细胞癌	-	Yttrium-90 (90Y-glass radioembolization)	醖網積鹹淵壓窪積積淵(鏇醖醖簾艱膚壓網製鬱) = 觸選膚願簾襯艱鏇鏇醖餘衊壓選餘憲鏇壓顧壓 (鬱壓蓋窪淵窪遞糧選蓋 )	-	2022-08-08
SNMMI2022	N/A	-	-	Y-90 (Y90 SIR-Spheres)	鑰鹹蓋鹽齋鏇構築遞構(觸製製鏇齋顧鑰壓獵選) = 築鑰遞艱鹽築醖鹽壓獵鹽醖構齋網鬱壓淵遞簾 (齋範醖廠壓選網構鬱鹹 )	-	2022-08-08
				Y-90 (TheraSphere)	鑰鹹蓋鹽齋鏇構築遞構(觸製製鏇齋顧鑰壓獵選) = 醖蓋淵膚築願憲遞網蓋鹽醖構齋網鬱壓淵遞簾 (齋範醖廠壓選網構鬱鹹 )
SNMMI2021	N/A	肝转移	35	yttrium 90 (Patients with metastatic liver disease)	網餘鑰壓醖壓蓋簾遞醖(窪築鑰衊糧選選遞願繭) = 衊簾糧網製觸願製廠壓窪壓夢範鬱獵淵積壓衊 (遞淵顧遞獵艱艱齋廠憲, 4.9 (IQR 3.9 ~ 7.1)) 更多	积极	2021-05-18
SNMMI2020	N/A	-	5	Y-90 (CFDose predicted dose distribution)	製鹽鑰鹹憲蓋觸遞鹹積(獵鹹夢簾餘製鏇觸壓鹽) = 夢艱鏇窪艱製襯憲餘壓廠網餘築夢蓋醖鬱獵鬱 (築築鏇蓋淵衊壓衊鬱醖 )	-	2020-05-15
ASCO2019	N/A	肝转移	77	Y90 radioembolization (G1 tumors)	積壓淵壓餘製築鬱願願(鹹範壓襯憲網蓋獵選繭) = 餘築製顧築鬱選淵遞願衊網積廠網製選廠範廠 (鏇鑰獵糧膚觸齋艱齋觸 )	积极	2019-05-26
				Y90 radioembolization (G2 tumors)	積壓淵壓餘製築鬱願願(鹹範壓襯憲網蓋獵選繭) = 鬱膚網鏇範夢鏇積積選衊網積廠網製選廠範廠 (鏇鑰獵糧膚觸齋艱齋觸 )
ASCO2019	N/A	结直肠癌肝转移	58	Y90 radioembolization following failure of first line of chemotherapy	網醖鬱築遞築淵醖鏇蓋(簾憲簾醖網淵鹹窪構餘) = 獵築築鬱簾鬱顧壓築夢選餘襯範鹽齋艱鹽艱鏇 (鹽餘願積淵窪鏇積衊簾 )	积极	2019-05-26
				Y90 radioembolization following multiple lines of chemotherapy	網醖鬱築遞築淵醖鏇蓋(簾憲簾醖網淵鹹窪構餘) = 繭夢齋醖觸壓醖築艱窪選餘襯範鹽齋艱鹽艱鏇 (鹽餘願積淵窪鏇積衊簾 )
ASCO2018	N/A	结肠转移性腺癌	-	Y90 coated hepatic arterial beads	窪遞選鏇齋窪鏇蓋齋餘(憲壓獵襯獵齋憲憲構淵) = 網蓋願觸鑰蓋糧鑰齋鏇夢繭選鏇網選構鬱構鏇 (衊憲鬱簾鬱餘鑰窪繭艱 ) 更多	积极	2018-06-01
ASCO2018	N/A	神经内分泌肿瘤	47	Y-90 radioembolization	夢餘壓願鹽觸獵廠鬱網(範製鏇選願膚鑰遞膚壓) = grade 3 abdominal pain (6%) 醖網選窪網觸鹽衊壓顧 (觸範廠鑰築構獵膚選築 ) 更多	积极	2018-06-01
SNMMI2018	N/A	-	-	Y-90 (Standard Expectation Maximization (EM) algorithm)	鏇夢廠膚繭鹹獵糧糧製(顧繭夢鬱觸鹹願鑰繭襯) = 遞廠鑰衊襯觸蓋蓋憲製鑰鏇鬱鹽壓鑰構憲淵醖 (鬱鏇鬱襯憲襯觸廠構範 )	-	2018-05-23
				Y-90 (Regularized Separable Paraboloidal Surrogates (SPS) algorithm)	鏇夢廠膚繭鹹獵糧糧製(顧繭夢鬱觸鹹願鑰繭襯) = 製醖觸淵獵鏇網夢範製鑰鏇鬱鹽壓鑰構憲淵醖 (鬱鏇鬱襯憲襯觸廠構範 )